Rising geriatric population propels demand in the Global Osteoarthritis Drugs Market

The research report by DataM Intelligence titled ‘Global Osteoarthritis Drugs Market – Size, Share and Forecast (2019-2026)’ analyses the scope and trends prevailing in this industry.

Global Osteoarthritis Drugs Market Dynamics
According to the United Nations (UN), an estimated 10% - 15% of all adults aged over 60 have some degree of OA, with the prevalence higher in women than men. UN estimated that by 2050 people aged over 60 will account for more than 20% of the world’s population, of which 15-20% (around 130 million people) are estimated to have symptomatic OA, and one-third of these people will be severely disabled (about 40 million people). Other factors such as the increasing awareness concerning degenerative bone diseases, the rise of obesity in the population, increasing incidents of occupational injury and trauma to the joints, expanding R&D activities and a robust pipeline portfolio of drugs with lesser side effects are expected to boost the global osteoarthritis drugs market.

Click the link to get a free sample of the report - https://www.datamintelligence.com/research-report/osteoarthritis-drugs-market

Global Osteoarthritis Drugs Market Segment Analysis
By Route of Administration, the global Osteoarthritis Drugs market includes Oral, Parenteral, and Topical. The topical segment holds a significant share of the market and is expected to grow at a steady pace as it is a preferred route of administration for patients with risks of sensitive stomach or heart problems, mainly seen in people older than 65.
By Drug Class, the global Osteoarthritis Drugs market is segmented into NSAIDs, Analgesics, Corticosteroids, Hyaluronic Acid, and Others. Non-steroidal Anti-inflammatory Drugs (NSAIDs) holds a substantial market share and is expected to grow during the forecast period. It is due to NSAIDs being the most common drug used to ease pain, stiffness, and inflammation that comes with arthritis.

Global Osteoarthritis Drugs Market Geographical Share
North America dominates the global osteoarthritis drugs market owing to the high prevalence of Osteoarthritis, growing obese population and high acceptance of Hyaluronic Acid-based drugs. According to the Arthritis Foundation, 2017, a conservative estimate indicating that about 54 million adults and almost 300,000 children were officially diagnosed with arthritis in the US and a recent study estimates that as many as 91 million Americans have arthritis. One in three people age 18-64 has arthritis. According to the Centers for Disease Control and Prevention, by 2040, an estimated 78.4 million (25.9% of the projected total adult population) adults aged 18 years and older will have doctor-diagnosed arthritis. Moreover, the high awareness among the people, government reimbursement policies, and the presence of significant players in the region are expected to supplement the growth of the regional osteoarthritis drugs market.

Global Osteoarthritis Drugs Market Competitive Trends
Key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches and strong pipeline drugs are other ways the leading players improve their market presence.

Read More information about the Global Osteoarthritis Drugs Market - https://www.datamintelligence.com/research-report/osteoarthritis-drugs-market

This report contains the following table of contents-

1. Osteoarthritis Drugs Market Methodology and Scope
1.1. Research methodology
1.2. Research Objective and Scope of the Report

2. Osteoarthritis Drugs Market – Market Definition and Overview

3. Osteoarthritis Drugs Market – Executive Summary
3.1. Market Snippet By Route of Administration
3.2. Market Snippet By Drug Class
3.3. Market Snippet By Distribution Channel
3.4. Market Snippet by Region
3.5. DataM CLO Scenario

4. Osteoarthritis Drugs Market – Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Geriatric Population
4.1.1.2. Increasing Incidence of Orthopedic Disorders
4.1.1.3. Driver 3
4.1.2. Restraints
4.1.2.1. High Side Effects and Safety Concerns
4.1.2.2. Restraint 2
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Osteoarthritis Drugs Market – Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Patent Analysis
5.4. Epidemiology Analysis
5.5. Pipeline Analysis

6. Osteoarthritis Drugs Market – By Route of Administration
6.1. Introduction
6.1.2. Market Size Analysis, By Route of Administration Segment
6.1.3. Market Attractiveness Index, By Route of Administration Segment
6.2. Oral
6.2.1. Introduction
6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.3. Parenteral
6.4. Topical

7. Osteoarthritis Drugs Market – By Drug Class
7.1. Introduction
7.1.2. Market Size Analysis, By Drug Class Segment
7.1.3. Market Attractiveness Index, By Drug Class Segment
7.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
7.2.1. Introduction
7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3. Analgesics
7.4. Corticosteroids
7.5. Hyaluronic Acid
7.6. Others

8. Osteoarthritis Drugs Market – By Distribution Channel
8.1. Introduction
8.1.2. Market Size Analysis, By Distribution Channel Segment
8.1.3. Market Attractiveness Index, By Distribution Channel Segment
8.2. Hospital Pharmacies
8.2.1. Introduction
8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies

9. Osteoarthritis Drugs Market – By Region
9.1. Introduction
9.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.1.3. Market Attractiveness Index, By Region
9.2. North America
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa

10. Osteoarthritis Drugs Market – Competitive Landscape
10.1. Competitive Scenario
10.2. Competitor Strategy Analysis
10.3. Comparative Product Portfolio Analysis
10.4. Market Positioning/Share Analysis
10.5. Mergers and Acquisitions Analysis

11. Osteoarthritis Drug Market – Company Profiles
11.1. Abbott Laboratories
11.1.1. Company overview
11.1.2. Product portfolio and description
11.1.3. Key highlights
11.1.4. Financial overview
11.2. Pfizer Inc.
11.3. Novartis AG
11.4. Zimmer Biomet Holdings Inc.
11.5. Sanofi
11.6. Bayer Healthcare
11.7. Iroko Pharmaceuticals
11.8. Johnson & Johnson
11.9. Smith & Nephew Plc
11.10. Merck & Co.
11.11. Eli Lilly and Company

12. Osteoarthritis Drugs Market – Premium Insights

13. Osteoarthritis Drugs Market – DataM
13.1. Appendix
13.2. About Us and Services
13.3 Contact Us

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and Automation among others.

1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

This release was published on openPR.